NextCure
NXTC
75 hedge funds and large institutions have $156M invested in NextCure in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 27 closing their positions.
99% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $633K
0.61% less ownership
Funds ownership: 6.13% → 5.52% (-0.61%)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
15% less funds holding
Funds holding: 88 → 75 (-13)
48% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
64% less capital invested
Capital invested by funds: $434M → $156M (-$278M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.5M |
| 2 |
Morgan Stanley
New York
|
+$7.55M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.56M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$4.1M |
| 5 |
Millennium Management
New York
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$21.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.1M |
| 5 |
Jennison Associates
New York
|
-$10M |
NXTC Hedge Fund Activity: Q3 2020 in Review
75 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q3 2020, worth a combined $156M — down 64% from $434M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of NXTC and 14 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 23 added.
The largest buyer was Citadel Advisors, adding an estimated $10.5M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $37.8M sold.
- 75 institutional investors held NextCure (NXTC) as of Q3 2020, down from 88 in Q2 2020.
- Funds reported $156M of NextCure stock for Q3 2020, down 64% quarter-over-quarter.
- 14 funds opened new NextCure positions in Q3 2020 and 27 closed out, a net change of -13 holders.
- The largest NextCure buyer in Q3 2020 was Citadel Advisors, an estimated $10.5M added.
- The largest NextCure seller in Q3 2020 was Lord, Abbett & Co, an estimated $37.8M sold.
Based on aggregated 13F filings for Q3 2020.